Dual Energy X-ray Absorptiometry (DXA) Comparison Hip Resurfacing Versus Total Hip Arthroplasty (THA)

A Dual Energy X-Ray Absorptiometry Comparison Of Periprosthetic Bone Loss Between Patients Undergoing Hip Resurfacing Surgery And Total Hip Arthroplasty

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01359527

Enrollment

Registered

2011-05-24

Start date

2008-12-31

Completion date

2018-11-30

Last updated

2019-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Hip

Keywords

Total Hip Replacement, Hip Resurfacing, Femoral Remodeling, Bone Loss, Bone Mineral Density, BMD, DXA, DEXA, THA

Brief summary

This study compares the change (loss) of bone mineral density (BMD) that occurs in the proximal femur after hip resurfacing and total hip replacement.

Detailed description

This study compares the change (loss) of bone mineral density (BMD) that occurs in the proximal femur after hip resurfacing and total hip replacement. The goal is to evaluate the bone loss in the proximal femur resulting from hip resurfacing surgery and to compare this to the bone loss in the proximal femur resulting from total hip arthroplasty.

Interventions

DEVICEHip Resurfacing

DEVICETotal Hip Arthroplasty

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Age of at least 20 years * Osteoarthritis * Elective Total Hip Arthroplasty / Resurfacing * Signed Informed Consent

Exclusion criteria

* Osteoporosis * Revisions * Femoral dysplasia * Trochanteric osteotomy * Inflammatory arthritis * Breast-feeding, pregnancy, or women of child-bearing potential without documentation of a negative pregnancy test and not utilizing contraception * Patients with a history of having taken or currently taking PTH, fluoride therapy or strontium ranelate or patients taking other chronic medications that in the Investigator's opinion are known to affect bone mineral density in a substantial way * Patients with severe medical condition(s) that in the view of the Investigator prohibits participation in the study * Use of any other investigational agent in the last 30 days

Design outcomes

Primary

Measure	Time frame	Description
Bone Mineral Density	Baseline, 6 weeks, 6 months, 1, 2, 3, 4, and 5 years post-operative	To evaluate the bone loss in the proximal femur resulting from hip resurfacing surgery and to compare this to the bone loss in the proximal femur resulting from total hip arthroplasty.

Secondary

Measure	Time frame	Description
Harris Hip Score	Pre-operative, 6 weeks, 6 months, 1, 2, 3, 4, and 5 years post-operative	Hip functional outcomes will be assessed using the Harris Hip Score

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026